LH Related Analyst Ratings
-
Jefferies Lifts PT on Laboratory Corp (LH) to $100
-
WallachBeth Capital Downgrades Laboratory Corp of America (LH) to Hold
-
Goldman Sachs Upgrades Laboratory Corporation of America (LH) to Neutral
-
ICON (ICLR) on Watch as Bristol-Myers Squibb (BMY) Adds New Lab Provider
-
UPDATE: Oppenheimer Starts Laboratory Corporation of America (LH) at Perform
-
Goldman Sachs Downgrades Laboratory Corporation of America (LH) to Sell
-
WallachBeth Capital Upgrades Laboratory Corporation of America (LH) to Buy
-
Davenport Downgrades Laboratory Corporation of America (LH) to Neutral
-
Macquarie Downgrades Laboratory Corporation of America (LH) to Neutral
-
Credit Suisse Assumes Laboratory Corporation of America (LH) at Neutral
-
WallachBeth Capital Starts Laboratory Corporation of America (LH) at Hold
-
LabCorp (LH) Could See a Hit from Aetna/Coventry Health Deal
-
LabCorp (LH) Could Be Worth More than $100/Share in LBO
-
Deutsche Bank Maintains a 'Hold' on Laboratory Corporation of America (LH); Leveraged Buy-out Model
-
Deutsche Bank Downgrades Laboratory Corporation of America (LH) to Hold; Finding it Harder to Stay Positive on Shares
-
William Blair Downgrades Laboratory Corporation of America (LH) to Market Perform
-
Piper Jaffray Downgrades Laboratory Corporation of America (LH) to Neutral
-
Canaccord Genuity Maintains a 'Buy' on Laboratory Corporation (LH); Q2 Preview: Successful Commercial Lab Business
-
Goldman Sachs Upgrades Laboratory Corporation of America (LH) to Neutral
-
UPDATE: Canaccord Genuity Starts Laboratory Corporation of America (LH) at Buy; Having The Keys Of Success
-
Raymond James Downgrades Laboratory Corporation of America (LH) Two Notches to 'Underperform'
-
Feltl Cuts MEDTOX (MTOX) to Hold Following Bid from Lab Corp.
-
Jefferies Maintains a 'Hold' on Laboratory Corporation (LH); Raising Numbers on Continued Shareholder Value
-
Auriga Reiteratess a 'Hold' on Laboratory Corporation (LH); Expect In-line to Slightly Better 4Q Results
-
Goldman Sachs Downgrades Laboratory Corporation of America (LH) to Sell
-
Barclays 2012 Top Picks: Becoming Somewhat More Optimistic - Signs of Progress, Growth and Soft Landings
-
Barclays Maintains an 'Overweight' on Laboratory Corporation (LH); Orchid Cellmark (ORCH) Deal Wins FTC Approval
-
Auriga Starts Laboratory Corporation of America (LH) at Hold
-
Barclays on Health Care Facilities: Perspectives on Medicare Reimbursement for Molecular Diagnostic Testing
-
Mizuho Securities Starts Laboratory Corporation of America (LH) at Neutral
-
Barclays maintains an 'Overweight' on Laboratory Corporation of America (LH); September Quarter Review
-
Jefferies Cuts Numbers on Laboratory Corporation (LH); Low Growth And Uncertain Reimbursement Make For A Good Hold
-
Susquehanna Starts Laboratory Corporation of America (LH) at Neutral
-
RBC Capital Downgrades Laboratory Corporation of America (LH) to Sector Perform, Cuts Price Target
-
Natixis Bleichroeder Starts Laboratory Corporation of America (LH) at Hold
-
UBS maintains a 'Neutral' on Laboratory Corporation (LH); Outlook Less Certain; Lowering Targets
-
Maxim Group Upgrades Laboratory Corporation of America (LH) to Buy
-
Barclays Maintains an 'Overweight' on Laboratory Corporation (LH); June Quarter Review - After the Call
-
Barclays Maintains an 'Overweight' on Laboratory Corp of America (LH); Medi-Cal Settlement a Non-Event
-
JPMorgan Starts Laboratory Corporation of America (LH) at Neutral
-
UBS on U.S. Healthcare Distribution - Labs: Q1 Clinical Lab Quarterly Preview
-
Raymond James Starts Laboratory Corporation of America (LH) at Outperform
-
Macquarie Starts Laboratory Corporation of America (LH) at Outperform
-
Quest Diagnostics (DGX) Added to Focus List at Credit Suisse
-
Caris & Co. Starts Laboratory Corporation of America (LH) at Above Average
-
Collins Stewart Starts MEDNEX (MD), DaVita (DVA), Lab Corp. (LH), Fresenius (FMS) at Buy, Quest (DGX) at Hold
-
BofA/Merrill Lynch Downgrades Laboratory Corporation of America (LH) to Neutral
-
Goldman Sachs Reinstates Laboratory Corporation of America (LH) at Neutral
-
Barclays Maintains an 'Overweight' on Laboratory Corporation of America (LH); Raising Price Target to $100
-
UBS Maintains a 'Neutral' on Laboratory Corporation of America (LH); What if LH Moves to Cash EPS?
Back to LH Stock Lookup
